Daily Brief Health Care: Hansoh Pharmaceutical, Wuxi Biologics, Tokyo Stock Exchange Tokyo Price Index Topix and more

In today’s briefing:

Hansoh Pharmaceutical (3692 HK): Strengthening Innovative Portfolio Through In-Licensing
Wuxi Biologics (2269.HK) 2022H1 – Hard to Achieve V-Share Rebound
More Companies Are Hiring Women Directors, but to Solve the Fundamental Problem of Diversity

Hansoh Pharmaceutical (3692 HK): Strengthening Innovative Portfolio Through In-Licensing

Hansoh Pharmaceutical (3692 HK) is strengthening its innovative drug pipeline. In August the company in-licensed one clinical stage drug candidate for women health, having large addressable market opportunity in China.
Earlier in May, entered into an exclusive license agreement with NiKang Therapeutics and obtained an exclusive license to develop and commercialize NKT2152 for the treatment of cancer within China.
Hansoh’s self-developed oncology drug is getting closer to the UK approval through its partner EQRx. The company received approval for one generic oncology drug in China.

WuXi Biologics released 2022H1 results. The Company maintained its growth momentum. We highlight some positive sides. However, gross profit margin decreased. Considering the future trend, margin performance is not optimistic.
A drop in demand has already occurred. Meanwhile, after the biologic drug boom has passed, the “low-hanging fruit” is gone, there could be more magnified cyclical problems for WuXi Biologics.
As an old generation CXO, it’s difficult for WuXi Biologics to achieve V-shaped rebound or hit new highs.2022 is a good time to offload. Investors can take advantage of it.

It shows that many companies still do not recognize the importance of diversity and that the hiring of women independent directors is merely a numbers game.
In Japan, there is the belief that a close-knit organization is more effective in achieving its goals, and there is a practice of excluding different opinions by emphasizing homogeneity.
In addition to the repeated disregard for women’s rights, the deep-seated problem of accepting this disregard is the reason diversity has not truly progressed.

💡 Before it’s here, it’s on Smartkarma

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network